secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001213900-24-020566
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma signs $33M clinical trial SOW with Eureka for EB103 Phase I/II NHL trial
--------------------------------------------------------------------------------

- Total fees of $33M for 20-patient Phase I/II trial of EB103 anti-CD19 ARTEMIS T-cell therapy in R/R B-cell NHL.
- Initial invoice of $3.5M due upon execution; $1.5M deposit before dosing; $1.375M per patient for 20 patients.
- Estimated dosing: 6 patients by end of 2024, 14 more by end of 2025; study close-out by end of 2025.
- Eureka Therapeutics, controlling shareholder of Estrella, provides services; includes cooperation for financing compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024020566/0001213900-24-020566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024020566/ea0201282-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-020566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer